We are proud to announce the publication of our latest research article titled “A global survey of health care workers’ awareness of non‐alcoholic fatty liver disease: The AwareNASH survey.” This article summarizes the findings of the AwareNASH survey, a project that was initiated and driven by Julius Clinical and our valued partner Leiden University Medical Center.
In collaboration with a multidisciplinary scientific committee, we designed a comprehensive survey to explore the knowledge, practices, and attitudes of healthcare workers toward the diagnosis and management of NAFLD/NASH. The survey was distributed to healthcare professionals from various disciplines across 88 countries, involving 613 respondents, including 488 physicians.
Our findings reveal a significant knowledge gap, with 64% of surveyed physicians underestimating the prevalence of NAFLD. Notably, general practitioners and cardiologists demonstrated the highest underestimation rates at 74% and 77%, respectively. Cardiologists, in particular, were least familiar with symptoms, diagnostic criteria, and management strategies. This study underscores the need for increased awareness and education surrounding NAFLD and NASH, especially among healthcare professionals treating patients with cardiometabolic comorbidities. We believe that by bridging this knowledge gap, we can enhance patient care and outcomes.
We would like to thank all the healthcare workers who participated in the survey. For more insights and details, Read the full article here
GRIPonMASH received significant EU funding to improve prevention and care of Metabolic dysfunction-Associated SteatoHepatitis (MASH)
Utrecht, The Netherlands, 05-02-2024 GRIPonMASH, a newly founded consortium consisting of 27 European institutions and companies, has bundled resources to bring about a transformational change in the detection and treatment of Metabolic Dysfunc...
Last Friday, the results of the CONVINCE trial were published in the prestigious New England Journal of Medicine. We are thrilled to announce that the CONVINCE study has shown that the use of high-dose hemodiafiltration led to a remarkable 23% low...